SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-049655
Filing Date
2022-04-25
Accepted
2022-04-25 16:22:07
Documents
11
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223704-1_def14a.htm DEF 14A 534845
2 GRAPHIC lg_sellaslifesciences-4clr.jpg GRAPHIC 25917
3 GRAPHIC sg_angelosmstergiou-bw.jpg GRAPHIC 9431
4 GRAPHIC sg_barbaraawood-bw.jpg GRAPHIC 9961
5 GRAPHIC tm223704d1-icon_internetbw.jpg GRAPHIC 4143
6 GRAPHIC tm223704d1-icon_mailbw.jpg GRAPHIC 1986
7 GRAPHIC tm223704d1-icon_telebwlr.jpg GRAPHIC 2489
8 GRAPHIC tm223704d1-pxy_proxy14c.jpg GRAPHIC 1514535
9 GRAPHIC tm223704d1-pxy_proxy24c.jpg GRAPHIC 1042992
10 GRAPHIC tm223704d1-pxy_proxy34c.jpg GRAPHIC 978505
11 GRAPHIC tm223704d1-pxy_proxy44c.jpg GRAPHIC 872591
  Complete submission text file 0001104659-22-049655.txt   6675780
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33958 | Film No.: 22849953
SIC: 2834 Pharmaceutical Preparations